VIRGINIA RETIREMENT SYSTEMS ET Al Raises Stock Holdings in Biohaven Ltd. $BHVN

VIRGINIA RETIREMENT SYSTEMS ET Al increased its stake in shares of Biohaven Ltd. (NYSE:BHVN) by 484.7% in the fourth quarter, HoldingsChannel reports. The firm owned 133,900 shares of the company’s stock after buying an additional 111,000 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Biohaven were worth $1,512,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. PNC Financial Services Group Inc. lifted its stake in shares of Biohaven by 113.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock worth $36,000 after purchasing an additional 1,268 shares during the last quarter. Focus Partners Wealth purchased a new stake in shares of Biohaven during the 3rd quarter worth $87,000. Tower Research Capital LLC TRC lifted its stake in shares of Biohaven by 198.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,031 shares of the company’s stock worth $113,000 after purchasing an additional 5,341 shares during the last quarter. Quantbot Technologies LP lifted its stake in shares of Biohaven by 1,097.8% during the 2nd quarter. Quantbot Technologies LP now owns 8,840 shares of the company’s stock worth $125,000 after purchasing an additional 8,102 shares during the last quarter. Finally, Osaic Holdings Inc. lifted its stake in shares of Biohaven by 150.5% during the 2nd quarter. Osaic Holdings Inc. now owns 9,791 shares of the company’s stock worth $147,000 after purchasing an additional 5,883 shares during the last quarter. 88.78% of the stock is currently owned by hedge funds and other institutional investors.

Biohaven Trading Down 3.1%

Biohaven stock opened at $8.74 on Friday. The stock has a 50-day moving average of $9.57 and a two-hundred day moving average of $10.65. The company has a debt-to-equity ratio of 1.87, a quick ratio of 7.41 and a current ratio of 7.41. The stock has a market cap of $1.32 billion, a PE ratio of -1.54 and a beta of 1.32. Biohaven Ltd. has a one year low of $7.48 and a one year high of $18.57.

Biohaven (NYSE:BHVN) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). On average, research analysts anticipate that Biohaven Ltd. will post -2.97 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on BHVN. Citigroup upped their price objective on Biohaven from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Thursday, April 2nd. Royal Bank Of Canada decreased their price objective on Biohaven from $23.00 to $22.00 and set an “outperform” rating for the company in a research note on Tuesday, May 5th. HC Wainwright decreased their price objective on Biohaven from $11.00 to $10.00 and set a “neutral” rating for the company in a research note on Wednesday, March 4th. Raymond James Financial reiterated a “strong-buy” rating on shares of Biohaven in a research note on Monday, March 9th. Finally, The Goldman Sachs Group upgraded Biohaven to a “strong-buy” rating in a research note on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Biohaven presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.27.

Biohaven Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.